Automate cervical cytology from sample to result
How we improve cervical cytology testing – scalable automation from sample to result
The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and automation levels needed, ensuring efficiency, precision, and full traceability across instruments from sample to results.
Low- to mid-volume laboratories: Achieve efficient and precise cytology testing in your lab
High-volume laboratories: Fulfil your automation needs with full-chain-of-custody across instruments, from sample to results
What can BD solutions for cytology testing automation do for your laboratory?
Automation of cytology testing associated with liquid-based cytology (LBC) may help you improve performance and flexibility in your lab thanks to increased consistency, reliability, throughput and walkaway time.4,9
BD solutions for
HPV testing
BD offers integrated end-to-end solutions for laboratories of all sizes and any cervical cancer screening method
ASC-US, atypical squamous cells of undetermined significance; HSIL, high-grade squamous intraepithelial lesions; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesions; Pap, Papanicolaou.
1. Rabaan AA et al. J Med Microbiol. 2018;67(5):676–80.
2. BD PrepMate™ Automated Accessory Operator’s Manual (500005571).
3. BD Totalys™ SlidePrep Instrument User’s Manual (500005570).
4. BD Totalys™ MultiProcessor User’s Manual (8089991).
5. BD Totalys™ MultiProcessor Throughput Testing Characterization Report (TC-14-1054).
6. PrepStain Plus Software – Surepath Regression Test Report (PD-08129-67R).
7. BD FocalPoint™ GS Imaging System Product Insert (500040544).
8. BD FocalPoint™ Slide Profiler Product Insert (7790419402).
9. Hoda RS et al. Diagn Cytopathol. 2013;41(3):257–78.
10. Nance KV. Diagn Cytopathol. 2007;35(3):148–53.
11. Rask J et al. Int J Cancer. 2014;134(9):2168–79.
12. Fremont-Smith M et al. Cancer. 2004;102(5):269–79.
13. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9.
14. Moriarty AT et al. Arch Pathol Lab Med. 2009;133(12):1912–6.
15. Rozemeijer K et al. BMJ. 2017;356:j504.
16. Gibb RK and Martens MG. Rev Obstet Gynecol. 2011;4(Suppl 1):S2–S11.
17. Rozemeijer K et al. Cancer Causes Control. 2016;27(1):15–25.